05:44 PM EDT, 05/28/2024 (MT Newswires) -- Sight Sciences ( SGHT ) said late Tuesday that results from a trial showed that patients treated with a single interventional eyelid procedure enabled by its TearCare technology after receiving Restasis for the first six months saw "clinically meaningful improvements" in the signs and symptoms of dry eye disease through month 12.

Phase 1 of the trial included 345 subjects, while in phase 2, 163 patients who had been treated with Restasis during phase 1 were crossed over to TearCare at the six-month visit and followed for six months through Month 12, the company said.

Phase 3 of the trial will provide long-term two-year data for the durability and procedural treatment effect of TearCare, Sight Sciences ( SGHT ) said.